MedPath

Comparison of Postoperative Pain Application of Alfentanil or Remifentanil in TIVA

Phase 4
Completed
Conditions
Postoperative Pain
Interventions
Registration Number
NCT05344911
Lead Sponsor
Xijing Hospital
Brief Summary

Total intravenous anesthesia (TIVA) is maintained by intermittent or continuous combined intravenous injection of a variety of short-acting intravenous anesthetics, which can provide safe and rapid induction, maintenance and termination of general anesthesia. It has a slight effect on respiration and circulation, strong controllability, short anesthetic recovery time, reduced postoperative nausea and vomiting (PONV) and quick discharge time, so it has been widely used in clinic. Functional endoscopic sinus surgery is a common method for the treatment of sinusitis and other diseases. The trauma of this operation is less. The use of TIVA during the operation can reduce the bleeding in the surgical field and is beneficial to the recovery of patients.

The combination of propofol and remifentanil is the most common in TIVA because of its fast pharmacokinetics and short half-life. However, the disadvantage of remifentanil is the lack of residual analgesic effect after termination of continuous infusion. As postoperative nasal packing can still bring postoperative pain, patients with severe discomfort caused by pain will have unexpected conditions such as surgical incision cracking and bleeding, which will affect the effect of operation and rehabilitation. Afentanil is another opioid drug with short effect and strong analgesic effect. Previous studies have shown that remifentanil-based TIVA has slightly higher postoperative pain and early use of analgesics than TIVA in discectomy. Because the effect of TIVA using Afentanil or remifentanil on postoperative pain in functional nasal endoscopic surgery is not clear, this study intends to observe the effect of TIVA on postoperative pain in patients undergoing functional nasal endoscopic surgery under general anesthesia, so as to optimize the clinical anesthetic scheme of this kind of minimally invasive surgery and provide clinical reference.

Detailed Description

This study intends to observe the effect of TIVA using afentanil or remifentanil on postoperative pain in patients undergoing functional nasal endoscopic surgery under general anesthesia.

Main indicators:

VAS score at 30 min after operation.

Secondary indicators:

VAS score of 60 min after operation. VAS score of 24h after operation. Number of cases of postoperative use of analgesics . Number of cases of postoperative adverse reactions.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
130
Inclusion Criteria
  • Age 18-65 years old
  • ASA Ⅰ-Ⅲ
  • patients undergoing functional endoscopic sinus surgery under general anesthesia.
Exclusion Criteria
  • Significant hypertension (diastolic blood pressure > 100mmHg) or hypotension (systolic . blood pressure < 100mmHg).
  • severe mental, cardiovascular, kidney or liver disease.
  • previous history of alcohol or drug abuse.
  • long-term use of painkillers before operation.
  • contraindications for any drugs used in the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
alfentanilPropofol combined with alfentanilAnesthesia maintenance:target-controlled infusion of propofol combined with afentanil
remifentanilPropofol combined with remifentanilAnesthesia maintenance:target-controlled infusion of propofol combined with remifentanil)
Primary Outcome Measures
NameTimeMethod
VAS scorePostoperative 30minutes

the digital rating scale (VAS) uses a number between 0 and 10 to indicate that there is no pain; a score of 1-3 means that a slight pain can be tolerated; a score of 4-6 indicates that it is bearable if it does not affect sleep; a score of 7-10 indicates that it is becoming more and more painful and unbearable, affecting appetite and sleep

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

YANLI

🇨🇳

XIan, Shanxi, China

© Copyright 2025. All Rights Reserved by MedPath